Sara Delfanti
Azienda Sanitaria Locale Alessandria(IT)
Publications by Year
Research Areas
Occupational and environmental lung diseases, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Pleural and Pulmonary Diseases
Most-Cited Works
- → Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial(2023)91 cited
- → Preoperative chemotherapy and carbon ions therapy for treatment of resectable and borderline resectable pancreatic adenocarcinoma: a prospective, phase II, multicentre, single-arm study(2019)40 cited
- → Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN)(2017)35 cited
- → Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial(2019)34 cited
- → Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors(2018)33 cited
- → IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.(2023)32 cited
- → Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer(2022)31 cited
- → Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer(2012)29 cited
- → Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study(2022)28 cited
- → In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status(2017)25 cited